Background: Aplastic anaemia is a condition characterized by
pancytopenia and unexplained bone marrow hypocellularity. Without
treatment, it is invariably fatal. However with the currently available
treatment options, patient survival is improving in the developed
countries. Methods: The study is a retrospective study. We reviewed
the cases of primary aplastic anaemia managed in our hospital over a
period of fifteen years. Results: A total of twenty five cases were
seen; out of which twenty had complete analyzable data. Management
consisted of transfusion support with packed red cells, platelet
concentrates and freshly collected unbanked blood; immunosuppressive
therapy was with methyl prednisolone. None of the patients had the
benefit of bone marrow/stem cell transplantation. Overall median
survival was 6.5 weeks. Conclusions: There is a clear need to ensure
the availability of proven therapeutic options for patients such as
bone marrow/stem cell transplantation and drugs such as cyclosporine
and antithymocyte globulin to improve on the present situation